VTGN News & Events

Vistagen announced the appointment of Angel Angelov, MD, MBA, as Chief Medical Officer, CMO, effective May 18, 2026. Dr. Angelov most recently served as CMO at Theranica

Vistagen announced preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who elected to participate in the OLE portion of PALISADE-3, administration of 3.2 microgram of fasedienol - taken as needed, up to six times per day in real-world, anxiety-provoking situations in daily life for up to 12 months - has been well-tolerated, with no new drug-related safety findings or trends identified. Exploratory efficacy data over the first four months of treatment demonstrated a clinically relevant improvement over time on both the clinician-administered Liebowitz Social Anxiety Scale and the Social Phobia Inventory. "Social anxiety disorder surfaces in the everyday moments of people's lives," said Shawn Singh, President and Chief Executive Officer of Vistagen. "Among our core goals is giving patients the ability to manage their anxiety in the daily life situations that matter most to them. We're continually encouraged by the improvements observed over time when patients in our open-label studies self-administer fasedienol as they feel it's needed."

Vistagen announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company's Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. The open label extension portion of the PALISADE-4 study remains ongoing. PALISADE-4 is a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in reducing anxiety symptoms in adults with social anxiety disorder during a simulated anxiety-provoking public speaking challenge conducted in a clinical setting using the Subjective Units of Distress Scale as the primary endpoint. Participants in the randomized portion of PALISADE-4 who chose to continue with the OLE portion of the study can use fasedienol in their daily lives up to six times per day for up to twelve months.

JonesResearch notes that Vistagen (VTGN) received an FDA "Study May Proceed" letter enabling further Phase 2 development of intranasal refisolone for menopausal vasomotor symptoms, also known as hot flashes, in the U.S. While refisolone's prior Phase 2a topline efficacy on hot-flash frequency "appears encouraging," the firm would interpret these results "with some caution," the analyst tells investors. If AbCellera's (ABCL) ABCL635 shows clean safety without any hepatic signals and target engagement comparable to Veohah/Lynkuet, the firm would believe the product "will be deemed very competitive," adds the analyst, who reiterates Buy rating and $11 price target on AbCellera shares ahead of Phase 1 update due on May 11.